BIOMARIN PHARMACEUTICAL INC Finance Lease, Principal Payments
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Finance Lease, Principal Payments of $889.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC finance lease, principal payments for the quarter ending 2024-06-30 was $18.00K, a 97.10% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC finance lease, principal payments for the quarter ending 2024-03-31 was $42.00K, a 95.86% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC finance lease, principal payments for the quarter ending 2023-12-31 was $45.00K, a 95.36% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC finance lease, principal payments for the quarter ending 2023-09-30 was $606.00K, a 18.13% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC finance lease, principal payments for fiscal 2025 was $889.00K, a 311.57% increase from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC finance lease, principal payments for fiscal 2024 was $216.00K, a 90.55% decline from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC finance lease, principal payments for fiscal 2023 was $2.29M, a 12.25% decline from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC finance lease, principal payments for fiscal 2022 was $2.60M, a 14.28% decline from fiscal 2021.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 6 month as first filed | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $889.00K 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $216.00K 10-K · filed 2026-02-26 | ||||
| 2024-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $60.00K 10-Q · filed 2024-08-05 | $105.00K derived: sum of 3 quarters · filed 2026-02-26 | $711.00K derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $42.00K 10-Q · filed 2024-04-26 | $87.00K derived: sum of 2 quarters · filed 2026-02-26 | $693.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.31M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $651.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.27M derived: sum of 3 quarters · filed 2026-02-26 | $2.29M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $606.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.23M derived: sum of 2 quarters · filed 2024-08-05 | $2.24M 10-Q · filed 2023-11-02 | $3.21M derived: sum of 4 quarters · filed 2024-08-05 | |
| 2023-06-30 | $621.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $1.64M 10-Q · filed 2024-08-05 | $2.60M derived: sum of 3 quarters · filed 2024-08-05 | $3.12M derived: sum of 4 quarters · filed 2024-08-05 | |
| 2023-03-31 | $1.01M 10-Q · filed 2024-04-26 | $1.98M derived: sum of 2 quarters · filed 2024-04-26 | $2.50M derived: sum of 3 quarters · filed 2024-04-26 | $3.05M derived: sum of 4 quarters · filed 2024-04-26 | |
| 2022-12-31 | $970.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.48M derived: sum of 2 quarters · filed 2024-02-26 | $2.04M derived: sum of 3 quarters · filed 2024-02-26 | $2.60M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $513.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.07M derived: sum of 2 quarters · filed 2023-11-02 | $1.64M 10-Q · filed 2023-11-02 | $2.18M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-06-30 | $556.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $1.12M 10-Q · filed 2023-08-02 | $1.67M derived: sum of 3 quarters · filed 2024-02-26 | $2.22M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-03-31 | $566.00K 10-Q · filed 2023-04-28 | $1.11M derived: sum of 2 quarters · filed 2024-02-26 | $1.66M derived: sum of 3 quarters · filed 2024-02-26 | $2.52M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2021-12-31 | $547.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.10M derived: sum of 2 quarters · filed 2024-02-26 | $1.96M derived: sum of 3 quarters · filed 2024-02-26 | $3.04M 10-K · filed 2024-02-26 | |
| 2021-09-30 | $551.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $1.41M derived: sum of 2 quarters · filed 2022-10-28 | $2.49M 10-Q · filed 2022-10-28 | $3.33M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $857.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.94M 10-Q · filed 2022-08-04 | $2.78M derived: sum of 3 quarters · filed 2023-02-27 | $6.81M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $1.08M 10-Q · filed 2022-04-29 | $1.92M derived: sum of 2 quarters · filed 2023-02-27 | $5.96M derived: sum of 3 quarters · filed 2023-02-27 | $7.18M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2020-12-31 | $838.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $4.87M derived: sum of 2 quarters · filed 2023-02-27 | $6.09M derived: sum of 3 quarters · filed 2023-02-27 | $6.92M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $4.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $5.26M derived: sum of 2 quarters · filed 2021-10-29 | $6.08M 10-Q · filed 2021-10-29 | $9.14M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $2.05M 10-Q · filed 2021-07-30 | $2.06M 10-Q · filed 2020-08-05 | $5.11M derived: sum of 3 quarters · filed 2022-02-25 | $5.79M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $823.00K 10-Q · filed 2020-05-01 | $3.88M derived: sum of 2 quarters · filed 2022-02-25 | $4.56M derived: sum of 3 quarters · filed 2022-02-25 | $5.24M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $3.74M derived: sum of 2 quarters · filed 2022-02-25 | $4.41M derived: sum of 3 quarters · filed 2022-02-25 | $5.09M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $681.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $1.35M derived: sum of 2 quarters · filed 2020-11-06 | $2.03M 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $672.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.35M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $674.00K 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |